Shahrabi Saeid, Ehsanpour Ali, Heidary Somayyeh, Shahjahani Mohammad, Behzad Masumeh Maleki
Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan.
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Oncol Rev. 2018 Oct 2;12(2):373. doi: 10.4081/oncol.2018.373. eCollection 2018 Jul 4.
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by the presence of JAK2 mutation. Thrombohemorrhagic as well as autoimmune or inflammatory phenomena are common clinical outcomes of these disorders. Recent studies have shown that abnormality in frequency and function of blood cells manifested by an alteration in CD markers' expression patterns play a key role in these complications. So, there may be a relationship between CD markers' expressions and prognosis of JAK2 positive MPNs. Therefore, in this review, we have focused on these abnormalities from the perspective of changing expressions of CD markers and assessment of the relationship between these changes with prognosis of JAK2 positive MPNs. It can be stated that the abnormal expression of a large number of CD markers can be used as a prognostic biomarker for clinical outcomes including thrombohememorrhagic events, as well as autoimmune and leukemic transformation in JAK2 positive MPNs. Considering the possible role of CD markers' expressions in JAK2 MPNs prognosis, further studies are needed to confirm the relationship between the expression of CD markers with prognosis to be able to find an appropriate therapeutic approach via targeting CD markers.
骨髓增殖性肿瘤(MPNs)是一类以存在JAK2突变特征的克隆性干细胞疾病。血栓出血以及自身免疫或炎症现象是这些疾病常见的临床结局。最近的研究表明,CD标志物表达模式改变所表现出的血细胞频率和功能异常在这些并发症中起关键作用。因此,CD标志物表达与JAK2阳性MPNs的预后之间可能存在关联。所以,在本综述中,我们从CD标志物表达变化的角度以及评估这些变化与JAK2阳性MPNs预后的关系方面,着重探讨了这些异常情况。可以说,大量CD标志物的异常表达可作为JAK2阳性MPNs临床结局的预后生物标志物,这些结局包括血栓出血事件以及自身免疫和白血病转化。考虑到CD标志物表达在JAK2 MPNs预后中可能发挥的作用,需要进一步研究来证实CD标志物表达与预后之间的关系,以便能够通过靶向CD标志物找到合适的治疗方法。